AL型淀粉样变性患者的血栓与出血并发症
该研究纳入450例连续AL型淀粉样变性患者,中位随访55个月,静脉血栓栓塞事件报告率为6%,动脉栓塞事件为5%,显著出血事件为9%且相关死亡率为19%。既往血栓史是静脉血栓栓塞的唯一独立预后变量(HR 9.3,p=0.001),肝功能受累、较高血清肌酐和较高基线VWF:Ag水平与出血风险相关;诊断后第一年血栓/出血累积概率较高,之后随访期间风险稳定在较低水平。
要点
- 静脉血栓栓塞事件报告率为6%,动脉栓塞事件为5%,显著出血事件为9%。
- 既往血栓史是静脉血栓栓塞的唯一独立预后变量(HR 9.3,p=0.001)。
- 显著出血事件的相关死亡率为19%。
核心结论
- 在AL型淀粉样变性患者中,血栓/动脉栓塞事件风险显著,但出血风险也高。
- 需要多参数评估以适当启动抗血栓或抗血小板治疗。
研究设计与样本
- 研究描述了450例连续AL型淀粉样变性患者的临床显著血栓/出血事件,中位随访55个月。
主要发现
- 静脉血栓栓塞事件在6%的患者中报告,动脉栓塞事件在5%的患者中报告。
- 较低白蛋白、较低eGFR、较高骨髓浸润、软组织受累、基于IMiD的治疗和既往血栓与静脉血栓栓塞风险相关;既往血栓是唯一独立预后变量(HR 9.3,p=0.001)。
- 冠状动脉疾病、既往动脉栓塞事件、24小时蛋白尿和较高血小板计数与动脉栓塞事件风险相关。
- 显著出血事件在9%的患者中报告,相关死亡率为19%。
- 肝脏受累、较高血清肌酐和较高基线VWF:Ag水平与出血风险相关。
临床怎么用
- 作者认为需要多参数评估以适当启动抗血栓或抗血小板治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haemostatic abnormalities and deregulated coagulation are common complications in AL amyloidosis. The relevant risks of thromboembolic and haemorrhagic events have not been thoroughly evaluated. To describe clinically significant thrombotic/haemorrhagic events in 450 consecutive patients with AL amyloidosis. Venous thromboembolic events (VTEs) were reported in 6% and arterial embolic events (AEEs) in 5% of patients, respectively, during a 55-month median follow-up. Lower albumin, lower eGFR, higher BM infiltration, soft tissue involvement, IMiD-based therapy and prior thrombosis were associated with VTE risk. Prior thrombosis was the only independent prognostic variable (HR 9.3, p = 0.001). Coronary arterial disease, prior AEE, 24-h proteinuria and higher platelet counts were associated with AEE risk. Significant bleeding events were reported in 9%, and associated mortality was 19%. Liver involvement, higher serum creatinine and higher baseline VWF:Ag levels were linked to bleeding risk. Using competing risk analysis, the cumulative probability of thrombosis/bleeding was higher during the first year following diagnosis, but a stable lower risk for both events remained for the duration of follow-up. In AL amyloidosis patients, the risk of thrombotic/arterial embolic events is significant, but the bleeding risk is also high. A multiparametric assessment is required to initiate anti-thrombotic or anti-platelet therapy appropriately.
引用
- Fotiou D, Theodorakakou F, Spiliopoulou S, et al. Thrombotic and bleeding complications in patients with AL amyloidosis. Br J Haematol. 2024. PMID: 38321638. doi:10.1111/bjh.19331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。